Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Clin Infect Dis. 2023 Nov 17;77(10):1432-1439. doi: 10.1093/cid/ciad389.
Intestinal microbiome contributes to the pathophysiology of acute gastrointestinal (GI) graft-versus-host disease (GvHD) and loss of microbiome diversity influences the outcome of patients after allogeneic stem cell transplantation (SCT). Systemic broad-spectrum antibiotics have been identified as a major cause of early intestinal dysbiosis.
In 2017, our transplant unit at the university hospital in Regensburg changed the antibiotic strategy from a permissive way with initiation of antibiotics in all patients with neutropenic fever independent of the underlying cause and risk to a restrictive use in cases with high likelihood of cytokine release syndrome (eg, after anti-thymocyte globulin [ATG] therapy). We analyzed clinical data and microbiome parameters obtained 7 days after allogeneic SCT from 188 patients with ATG therapy transplanted in 2015/2016 (permissive cohort, n = 101) and 2918/2019 (restrictive cohort, n = 87).
Restrictive antibiotic treatment postponed the beginning of antibiotic administration from 1.4 ± 7.6 days prior to 1.7 ± 5.5 days after SCT (P = .01) and significantly reduced the duration of antibiotic administration by 5.8 days (P < .001) without increase in infectious complications. Furthermore, we observed beneficial effects of the restrictive strategy compared with the permissive way on microbiome diversity (urinary 3-indoxylsulfate, P = .01; Shannon and Simpson indices, P < .001) and species abundance 7 days post-transplant as well as a positive trend toward a reduced incidence of severe GI GvHD (P = .1).
Our data indicate that microbiota protection can be achieved by a more careful selection of neutropenic patients qualifying for antibiotic treatment during allogeneic SCT without increased risk of infectious complications.
肠道微生物群有助于急性胃肠道(GI)移植物抗宿主病(GvHD)的病理生理学,微生物多样性的丧失会影响异基因干细胞移植(SCT)后患者的结局。全身广谱抗生素已被确定为早期肠道失调的主要原因。
2017 年,我们所在的雷根斯堡大学医院的移植科改变了抗生素策略,从一种宽松的方式转变为在所有中性粒细胞减少性发热的患者中使用抗生素,而不考虑潜在原因和风险,转变为在有细胞因子释放综合征高可能性的情况下使用(例如,在抗胸腺细胞球蛋白[ATG]治疗后)。我们分析了 2015/2016 年接受 ATG 治疗的 188 例异基因 SCT 患者(宽松队列,n=101)和 2018/2019 年(限制队列,n=87)的临床数据和 SCT 后 7 天获得的微生物组参数。
限制抗生素治疗将抗生素治疗的开始时间从 SCT 前 1.4±7.6 天推迟到 SCT 后 1.7±5.5 天(P=0.01),并显著减少了 5.8 天的抗生素治疗时间(P<0.001),而没有增加感染并发症。此外,与宽松策略相比,限制策略对微生物组多样性(尿 3-吲哚硫酸酯,P=0.01;香农和辛普森指数,P<0.001)和移植后 7 天的物种丰度具有有益的影响,并且严重 GI GvHD 的发生率呈下降趋势(P=0.1)。
我们的数据表明,通过更仔细地选择有资格接受抗生素治疗的中性粒细胞减少患者,可以在不增加感染并发症风险的情况下,实现对微生物群的保护。